Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection

Alcaide, A.J.; Barrera, M.D.G. Dominguez; Habicheyn, S; López, Nelson; Mendiola, MV; Herrera, Enrique

doi:10.1111/j.1468-3083.2008.02693.x

Cited by 14 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This would appear to be supported by reports of the use of anti-TNF drugs in more than 110 HCV infected patients (summarized in Table 2). 28,31,32,[43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60] In untreated subjects, HCV viral loads exhibit marked variation. Similar variation is seen in longitudinal studies of the effects of anti-TNF drugs in such patients, although significant elevations in HCV viral load are rare.…”

Section: Hepatitis C Virusmentioning

confidence: 99%

See 1 more Smart Citation

Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease

Shale

Seow

Coffin

et al. 2009

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Anti‐Tumour necrosis factor (TNF) therapy is now well established in the treatment of inflammatory bowel disease and the risk of opportunistic infection is recognized. However, specific considerations regarding screening, detection, prevention and treatment of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease are not widely adopted in practice. Aim To provide a detailed and comprehensive review of the relevance of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease. Methods Literature search was conducted using Medline, Pubmed and Embase using the terms viral infection, hepatitis, herpes, CMV, EBV, HPV, anti‐TNF, infliximab, adalimumab, certolizumab pegol and etanercept. Hepatitis B and C and HIV had the largest literature associated and these have been summarized in Tables. Results Particular risks are associated with the use of anti‐TNF drugs in patients with hepatitis B infection, in whom reactivation is common unless anti‐viral prophylaxis is used. Reactivation of herpes zoster is the most common viral problem associated with anti‐TNF treatment, and may be particularly severe. Primary varicella infection may present with atypical features in patients on anti‐TNF. Conclusion Appreciation of risks of chronic viral disease associated with anti‐TNF therapy may permit early recognition, prophylaxis and treatment.

show abstract

Section: Hepatitis C Virusmentioning

confidence: 99%

“…This would appear to be supported by reports of the use of anti‐TNF drugs in more than 110 HCV infected patients (summarized in Table 2). 28, 31, 32, 43–60 …”

Section: Consideration One – Chronic Viral Infectionsmentioning

confidence: 99%

Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease

Shale

Seow

Coffin

et al. 2009

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Apesar de ser comum a presença concomitante de psoríase e síndrome de Down apenas estão descritos poucos casos clínicos na literatura [4][5][6][7] , incluindo a associação a artropatia psoriática 8 .…”

Section: Discussionunclassified

“…O tratamento destes doentes pode ser difícil não só pelo risco de toxicidade órgão específica mas também pela maior suscetibilidade a infeções e maior incidência de malignidade nestes doentes. Tem sido discutido a segurança e eficácia de agentes biológicos no tratamento de doentes com síndrome de Down e psoríase 4,13 .…”

Section: Discussionunclassified

Psoríase Em Placas Em Doente Com Síndrome De Down - Potencial Patofisiologia Comum E Dificuldade De Tratamento

Araújo

Resende

Vieira

et al. 2015

SPDV

View full text Add to dashboard Cite

Introdução: A psoríase ocorre em até 8% dos doentes com síndrome de Down e, embora mal caraterizada, parece estar correlacionada com desequilíbrio imunológico das células Th1e alterações bioquímicas nos nucleótidos cíclicos.Caso clínico: Doente do sexo feminino, 38 anos, com síndrome de Down e antecedentes de psoríase (PASI inicial de 30) desde os 18 anos de idade. Medicada com ciclosporina e metotrexato e subsequentemente foi medicada com etanercept, adalimumab e ustecinumab por perda progressiva de resposta (PASI atual de 10).Conclusão: Descreve-se este caso pela má resposta aos tratamentos, incluindo diversos agentes biológicos. A potencial baixa adesão à terapêutica e a disfunção imunológica poderão limitar as opções terapêuticas.

show abstract

“…In this context, a number of small case series or anecdotal cases have been reported in which etanercept, efalizumab and alefacept do not induced HCV exacerbation. Of note, mild improvement in viral load and/or liver function tests were also observed in many of these cases [151,[157][158][159][160][161][162][163][164][165][166][167][168][169][170]. Only in one case, described by Ventura and coworkers [163], a significant increase of viral load (from 1.52×10 4 to 1.94×10 6 IU/mL), not coupled with increased liver enzymes, was observed after a 6-month therapy and led to treatment discontinuation.…”

Section: Hcv Settingmentioning

confidence: 99%

The Skin and Viral Liver Disease

Mastrolonardo¹

2013

Practical Management of Chronic Viral Hepatitis

View full text Add to dashboard Cite

Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection

Cited by 14 publications

References 6 publications

Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease

Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease

Psoríase Em Placas Em Doente Com Síndrome De Down - Potencial Patofisiologia Comum E Dificuldade De Tratamento

The Skin and Viral Liver Disease

Contact Info

Product

Resources

About